TELA Bio Lowers 2026 Growth Guidance to 8% After Sales Reorg
TELA Bio set fiscal 2026 revenue guidance at least 8% growth, lowered from previous expectations to accommodate extensive commercial reorganization and new hires. The company forecasts European OviTex sales, PRS expansion with larger product launches, and anticipates returning to double-digit growth in the second half as changes integrate.
1. Fiscal 2026 Guidance At 8% Growth
Antony Koblish, President and CEO, set fiscal 2026 revenue guidance at a minimum of 8% growth, lowered from earlier targets to accommodate a large-scale commercial reorganization and extensive new hires.
2. Commercial Restructuring Causes Q1 Disruption
Territory realignment into smaller, high-population segments has temporarily disrupted Q1 performance, as the company balances short-term sales fluctuation with long-term efficiency gains expected by quarter end.
3. Product Segment Outlook For 2026
European OviTex sales are expected to remain strong, PRS revenue should grow with larger product launches and new technologies, and LIQUIFIX is projected to expand significantly from its smaller base.
4. Anticipated Return To Double-Digit Growth
The company anticipates outgrowing the mid-single-digit market rate and returning to double-digit revenue growth in the second half of 2026 once structural changes are fully integrated.